NES and myeloproliferative disorder: A link between increase of nestin+ MSCs and reduced myelofibrosis was also found in our clinical phase II trial using Mirabegron, a β−3 sympathomimetic agonist, that corrected the damage inflicted by the MPN clone on the nestin+ MSCs40.